AAPL   322.10 (+0.08%)
MSFT   183.63 (+0.44%)
FB   229.85 (-0.89%)
GOOGL   1,433.99 (-0.06%)
AMZN   2,468.60 (-0.10%)
NVDA   351.37 (-0.25%)
BABA   213.60 (+3.40%)
MU   46.49 (+0.30%)
TSLA   894.99 (-0.35%)
AMD   52.89 (-1.40%)
T   30.91 (-0.06%)
GILD   73.23 (-2.57%)
NFLX   424.26 (-0.39%)
BAC   24.81 (+0.81%)
BA   153.51 (+1.40%)
AAPL   322.10 (+0.08%)
MSFT   183.63 (+0.44%)
FB   229.85 (-0.89%)
GOOGL   1,433.99 (-0.06%)
AMZN   2,468.60 (-0.10%)
NVDA   351.37 (-0.25%)
BABA   213.60 (+3.40%)
MU   46.49 (+0.30%)
TSLA   894.99 (-0.35%)
AMD   52.89 (-1.40%)
T   30.91 (-0.06%)
GILD   73.23 (-2.57%)
NFLX   424.26 (-0.39%)
BAC   24.81 (+0.81%)
BA   153.51 (+1.40%)
AAPL   322.10 (+0.08%)
MSFT   183.63 (+0.44%)
FB   229.85 (-0.89%)
GOOGL   1,433.99 (-0.06%)
AMZN   2,468.60 (-0.10%)
NVDA   351.37 (-0.25%)
BABA   213.60 (+3.40%)
MU   46.49 (+0.30%)
TSLA   894.99 (-0.35%)
AMD   52.89 (-1.40%)
T   30.91 (-0.06%)
GILD   73.23 (-2.57%)
NFLX   424.26 (-0.39%)
BAC   24.81 (+0.81%)
BA   153.51 (+1.40%)
AAPL   322.10 (+0.08%)
MSFT   183.63 (+0.44%)
FB   229.85 (-0.89%)
GOOGL   1,433.99 (-0.06%)
AMZN   2,468.60 (-0.10%)
NVDA   351.37 (-0.25%)
BABA   213.60 (+3.40%)
MU   46.49 (+0.30%)
TSLA   894.99 (-0.35%)
AMD   52.89 (-1.40%)
T   30.91 (-0.06%)
GILD   73.23 (-2.57%)
NFLX   424.26 (-0.39%)
BAC   24.81 (+0.81%)
BA   153.51 (+1.40%)
Log in

NASDAQ:ASMBAssembly Biosciences Stock Price, Forecast & News

$18.70
-0.12 (-0.64 %)
(As of 06/2/2020 02:44 PM ET)
Add
Compare
Today's Range
$17.71
Now: $18.70
$19.13
50-Day Range
$15.67
MA: $18.77
$21.93
52-Week Range
$8.13
Now: $18.70
$25.07
Volume202,051 shs
Average Volume184,832 shs
Market Capitalization$611.86 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in two Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in investigational new drug-enabling studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn's disease, irritable bowel syndrome, non-alcoholic steatohepatitis, and immuno-oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.
Read More
Assembly Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.34 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ASMB
CUSIP92282210
Phone833-509-4583

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.96 million
Book Value$10.49 per share

Profitability

Net Income$-97,630,000.00
Net Margins-601.75%

Miscellaneous

Employees95
Market Cap$611.86 million
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive ASMB News and Ratings via Email

Sign-up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter.

Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions

How has Assembly Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Assembly Biosciences' stock was trading at $15.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ASMB shares have increased by 19.9% and is now trading at $18.70. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Assembly Biosciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Assembly Biosciences.

When is Assembly Biosciences' next earnings date?

Assembly Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Assembly Biosciences.

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences Inc (NASDAQ:ASMB) announced its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.98) by $0.22. The biopharmaceutical company had revenue of $4.08 million for the quarter, compared to analyst estimates of $3.82 million. Assembly Biosciences had a negative net margin of 601.75% and a negative return on equity of 45.43%. View Assembly Biosciences' earnings history.

What price target have analysts set for ASMB?

4 Wall Street analysts have issued 1-year target prices for Assembly Biosciences' stock. Their forecasts range from $30.00 to $74.00. On average, they expect Assembly Biosciences' share price to reach $44.67 in the next twelve months. This suggests a possible upside of 138.9% from the stock's current price. View analysts' price targets for Assembly Biosciences.

Has Assembly Biosciences been receiving favorable news coverage?

Press coverage about ASMB stock has been trending positive this week, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Assembly Biosciences earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutAssembly Biosciences.

Who are some of Assembly Biosciences' key competitors?

What other stocks do shareholders of Assembly Biosciences own?

Who are Assembly Biosciences' key executives?

Assembly Biosciences' management team includes the following people:
  • Mr. Derek A. Small, Co-Founder, Pres, CEO & Director (Age 43)
  • Dr. Uri A. Lopatin, Co-Founder, Chief Medical Officer and VP of R&D (Age 47)
  • Dr. Richard J. Colonno, Exec. VP & Chief Scientific Officer of Virology Operations (Age 69)
  • Mr. Thomas E. Rollins, Exec. Officer (Age 63)
  • Mr. David J. Barrett CPA, Consultant (Age 43)

What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

Who are Assembly Biosciences' major shareholders?

Assembly Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Jennison Associates LLC (7.16%), BlackRock Inc. (7.03%), Wellington Management Group LLP (4.40%), Victory Capital Management Inc. (3.99%), Victory Capital Management Inc. (3.99%) and Franklin Resources Inc. (1.85%). Company insiders that own Assembly Biosciences stock include Derek A Small, Jacqueline Sybil Papkoff, Richard James Colonno, Uri A Lopatin and William R Ringo. View institutional ownership trends for Assembly Biosciences.

Which institutional investors are selling Assembly Biosciences stock?

ASMB stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., SG Americas Securities LLC, Wellington Management Group LLP, Two Sigma Investments LP, Blair William & Co. IL, Victory Capital Management Inc., Victory Capital Management Inc., and Deutsche Bank AG. Company insiders that have sold Assembly Biosciences company stock in the last year include Jacqueline Sybil Papkoff, and Richard James Colonno. View insider buying and selling activity for Assembly Biosciences.

Which institutional investors are buying Assembly Biosciences stock?

ASMB stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Emerald Mutual Fund Advisers Trust, Nuveen Asset Management LLC, Atom Investors LP, Morgan Stanley, Morgan Stanley, State Street Corp, and Bailard Inc.. View insider buying and selling activity for Assembly Biosciences.

How do I buy shares of Assembly Biosciences?

Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Assembly Biosciences' stock price today?

One share of ASMB stock can currently be purchased for approximately $18.70.

How big of a company is Assembly Biosciences?

Assembly Biosciences has a market capitalization of $611.86 million and generates $15.96 million in revenue each year. The biopharmaceutical company earns $-97,630,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis. Assembly Biosciences employs 95 workers across the globe.

What is Assembly Biosciences' official website?

The official website for Assembly Biosciences is www.assemblybio.com.

How can I contact Assembly Biosciences?

Assembly Biosciences' mailing address is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 833-509-4583 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.